DrugPatentWatch Database Preview

ZERBAXA Drug Profile

  Purchase this report

or, see our see our flat-rate plans

« Back to Dashboard

When do Zerbaxa patents expire, and what generic alternatives are available?

Zerbaxa is a drug marketed by Cubist Pharms Llc and is included in one NDA. There are seven patents protecting this drug.

This drug has forty-nine patent family members in twenty-seven countries.

The generic ingredient in ZERBAXA is ceftolozane sulfate; tazobactam sodium. One supplier is listed for this compound. Additional details are available on the ceftolozane sulfate; tazobactam sodium profile page.

Summary for ZERBAXA

International Patents:	49
US Patents:	7
Applicants:	1
NDAs:	1
Suppliers / Packagers:	1
Clinical Trials:	2
Formulation / Manufacturing:	see details
DailyMed Link:	ZERBAXA at DailyMed

Pharmacology for ZERBAXA

Ingredient-type	Cephalosporins
Drug Class	Cephalosporin Antibacterial beta Lactamase Inhibitor
Mechanism of Action	beta Lactamase Inhibitors

US Patents and Regulatory Information for ZERBAXA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cubist Pharms Llc	ZERBAXA	ceftolozane sulfate; tazobactam sodium	POWDER;IV (INFUSION)	206829-001	Dec 19, 2014		RX	Yes	Yes			Y	Y
Cubist Pharms Llc	ZERBAXA	ceftolozane sulfate; tazobactam sodium	POWDER;IV (INFUSION)	206829-001	Dec 19, 2014		RX	Yes	Yes			Y	Y
Cubist Pharms Llc	ZERBAXA	ceftolozane sulfate; tazobactam sodium	POWDER;IV (INFUSION)	206829-001	Dec 19, 2014		RX	Yes	Yes			Y
Cubist Pharms Llc	ZERBAXA	ceftolozane sulfate; tazobactam sodium	POWDER;IV (INFUSION)	206829-001	Dec 19, 2014		RX	Yes	Yes				Y

  Purchase this report

or, see our see our flat-rate plans

Non-Orange Book US Patents for ZERBAXA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
9,044,485	Ceftolozane antibiotic compositions

  Purchase this report

or, see our see our flat-rate plans

International Patents for ZERBAXA

Country	Document Number	Estimated Expiration
Eurasian Patent Organization	201591712
Brazil	0315188
New Zealand	700372
China	100343260

Supplementary Protection Certificates for ZERBAXA

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
C0004	France		PRODUCT NAME: CEFTOLOZANE,EVENTUELLEMENT SOUS LA FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE,PLUS PARTICULIEREMENT UN SEL D'ACIDE SULFURIQUE; REGISTRATION NO/DATE: EU/1/15/1032 20150922
15/074	Ireland		PRODUCT NAME: CEFTOLOZANE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR A SULFURIC ACID SALT; REGISTRATION NO/DATE: EU/1/15/1032/001 20150918
0793	Netherlands		PRODUCT NAME: CEFTOLOZAAN OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN IN HET BIJZONDER EEN ZWAVELZUURZOUT; REGISTRATION NO/DATE: EU/1/15/1032 20150922
943	Luxembourg		PRODUCT NAME: CEFTOLOZANE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, EN PARTICULIER UN SEL D'ACIDE SULFURIQUE (ZERBAXA); FIRST REGISTRATION: 20150922